Real-World Results Confirm Dosing ZOMETA® To Prostate Cancer Patients With SREs Every 3 - 4 Weeks
ZOMETA - Zoledronic AcidZOMETA - Zoledronic Acid Novartis Oncology
HomeZOMETA - International SiteZOMETA - US ResidentsZOMETA - Country Sites
ZOMETA - English ZOMETA - Deutsch ZOMETA - Espanol ZOMETA - Francais ZOMETA - Italiano
ZOMETA-Videos
Blue Arrow View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
ZOMETA European Summary of Product Characteristics
Blue Arrow For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics
 
About ZOMETA: defend against SREs across a broad range of tumour types

Page  1 2 3 4


Real-world results confirm the benefits of dosing ZOMETA® every 3 to 4 weeks15


Rate of SREs by dosing reimen15*
*There are limitations to this study because the results are from a retrospective claims database analysis.



  • Treatment with ZOMETA 4 mg every 3 to 4 weeks significantly reduced the rate of skeletal morbidity (measured as number of events per month) vs no treatment15
  • No other dosing schedule is proven to protect patients from SREs2,12-14


Using alternative dosing schedules significantly compromises the
benefits of ZOMETA15





Page  1 2 3 4